develops and commercializes therapeutics. The company concentrated primarily on antiviral drugs to treat patients infected with HIV, hepatitis B, or influenza. On November 28th, I Know First published an article titled “Gilead Sciences: Is Gilead Taking The Lead? - A Bullish Fundamental & Algorithmic Perspective” on Seeking Alpha. The algorithm had a signal strength of 40.00 and a predictability indicator of 0.26 for Gilead Sciences over the one-month time horizon. GILD stock has already increased 5.22% since the publication of the article.
Disclaimer:
I Know First-Daily Market Forecast, does not provide personal investment or financial advice to individuals, or act as personal financial, legal, or institutional investment advisors, or individually advocate the purchase or sale of any security or investment or the use of any particular financial strategy. All investing, stock forecasts and investment strategies include the risk of loss for some or even all of your capital. Before pursuing any financial strategies discussed on this website, you should always consult with a licensed financial advisor.
